Cargando…
1417. Evaluating the Dissonance Between C(max) and AUC with Clinically Utilized Aminoglycoside (AG) Dosing Regimens: Use of Tobramycin (TOB) Against Pseudomonas aeruginosa (PA) as a Case Study
BACKGROUND: Current dogma suggests optimizing AG doses based on peak concentration (C(max)), without consideration of daily drug exposure (AUC(24)). The correlation between attainment of the TOB pharmacokinetic-pharmacodynamic (PK-PD) targets, C(max):MIC and AUC(24):MIC ratio was explored using a TO...
Autores principales: | Onufrak, Nikolas J, Bhavnani, Sujata M, Pogue, Jason M, Rubino, Christopher M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253600/ http://dx.doi.org/10.1093/ofid/ofy210.1248 |
Ejemplares similares
-
2562. Re-Appraisal of Aminoglycoside (AG) Susceptibility Testing Breakpoints Based on the Application of Pharmacokinetics–Pharmacodynamics (PK-PD) and Contemporary Microbiology Surveillance Data
por: Bhavnani, Sujata M, et al.
Publicado: (2018) -
Oxidized Chitosan-Tobramycin (OCS-TOB) Submicro-Fibers for Biomedical Applications
por: Li, Zhen, et al.
Publicado: (2022) -
The Neurospora crassa TOB Complex: Analysis of the Topology and Function of Tob38 and Tob37
por: Lackey, Sebastian W. K., et al.
Publicado: (2011) -
703. Mechanisms of High-Level Ceftolozane/Tazobactam (CT) Resistance Against Pseudomonas aeruginosa and Synergy Between CT and Tobramycin (TOB)
por: So, Wonhee, et al.
Publicado: (2018) -
1590. Updated Aminoglycoside (AG) MIC Breakpoints (BP) to Minimize Adverse Events and Improve Outcome: Impact on Susceptibility (S) Rates
por: Pfaller, Michael A, et al.
Publicado: (2019)